1
|
Dariane C, Chierigo F, Ouellet V, Delvoye N, Jammal MP, Bégin LR, Paradis JB, Mes-Masson AM, Karakiewicz PI, Saad F. Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data. Fr J Urol 2024; 34:102544. [PMID: 37858379 DOI: 10.1016/j.purol.2023.09.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 09/28/2023] [Indexed: 10/21/2023]
Abstract
INTRODUCTION Active surveillance (AS) has emerged as a primary management strategy for low-risk prostate cancer (PC) patients. We aimed to assess AS uptake over a 1-year snapshot throughout Quebec and to compare it to 2010 multicentric Canadian data. METHODS A retrospective chart review and data collection was performed in 1 academic and 2 non-academic community centres from Quebec, among men identified in 2016 with localized T1c-T2c PC on biopsy, fulfilling NCCN criteria of low-risk (LR)-PC, including very-low-risk (VLR) and non-VLR-PC, and favourable-intermediate risk (FIR)-PC. AS adherence was defined when chosen as initial strategy, without any radical treatment within 6 months. RESULTS Overall, 259 patients fulfilled the inclusion criteria with 50.2% of VLR-PC patients. At 6 months, 81% patients in the LR group and 65% in the FIR group were considered as adherent to AS, in both centres, but with an increased use of AS in the community centres compared to 2010 data. The rates of AS maintenance decreased at 12 months to respectively 69% and 58%. Among the VLR group, the rate of initiation was 98% and decreased to 85% at 12 months. CONCLUSION Our data suggest that the majority of low-risk PC patients indeed initiated an AS in 2016, with even a greater proportion of VLR-PC patients compared to 2010. This ideal strategy should be encouraged and improved at 12 months, and assessed with recent data and longer follow-up. LEVEL OF EVIDENCE: 4
Collapse
Affiliation(s)
- C Dariane
- Institut du cancer de Montréal, centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM), Montréal, Canada; Department of Urology, hôpital européen Georges-Pompidou, Paris University, 20, rue Leblanc, 75015 Paris, France.
| | - F Chierigo
- Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Canada
| | - V Ouellet
- Institut du cancer de Montréal, centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM), Montréal, Canada
| | - N Delvoye
- Institut du cancer de Montréal, centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM), Montréal, Canada
| | - M-P Jammal
- Centre de santé et des services sociaux de Laval, Laval, QC, Canada
| | - L R Bégin
- Centre intégré de santé et des services sociaux des Laurentides, St-Eustache, QC, Canada
| | - J-B Paradis
- Centre de santé et des services sociaux de Chicoutimi, Chicoutimi, QC, Canada
| | - A-M Mes-Masson
- Institut du cancer de Montréal, centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM), Montréal, Canada
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Canada
| | - F Saad
- Institut du cancer de Montréal, centre de recherche du centre hospitalier de l'université de Montréal (CRCHUM), Montréal, Canada; Department of Surgery, Division of Urology, centre hospitalier de l'université de Montréal (CHUM), Montréal, Canada
| |
Collapse
|
2
|
Flammia RS, Lavigne D, Tian Z, Saad F, Anceschi U, Gallucci M, Leonardo C, Preisser F, Mandel P, Chun FKH, Karakiewicz PI, Delouya G, Taussky D, Hoeh B. Trial Participation is Not Associated with Better Biochemical Recurrence-free Survival in a Large Cohort of External Beam Radiotherapy-Treated Intermediate- and High-Risk Prostate Cancer Patients. Clin Oncol (R Coll Radiol) 2023; 35:e77-e84. [PMID: 36115747 DOI: 10.1016/j.clon.2022.08.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 08/04/2022] [Accepted: 08/22/2022] [Indexed: 01/06/2023]
Abstract
AIMS There is a widespread belief that outcomes of cancer patients treated within clinical trials might not be representative of the outcomes obtained within standard clinical settings. We sought to investigate the effect of trial participation on biochemical recurrence (BCR) in localised, D'Amico intermediate- and high-risk prostate cancer patients treated with external beam radiotherapy (EBRT). MATERIALS AND METHODS We relied on a study population treated with EBRT between January 2001 and January 2021 at a single tertiary care centre, stratified according to trial enrolment. Separate Kaplan-Meier and multivariable Cox regression models tested BCR-free survival at 60 months within intermediate- and high-risk EBRT patients, after adjustment for covariables. Additionally, the analyses were refitted after inverse probability treatment weighting was performed separately for both risk subgroups. RESULTS Of 932 eligible patients, 635 (68%) and 297 (32%) had intermediate- and high-risk prostate cancer, respectively. Overall, 53% of patients were trial participants. BCR rates were 11 versus 5% (P = 0.27) and 12 versus 14% (P = 0.08) in trial participants versus non-participants for intermediate- and high-risk subgroups, respectively. Differences in patient and clinical characteristics were recorded. Trial participation status failed to reach predictor status in multivariable Cox regression models for BCR in both intermediate-risk (hazard ratio 1.34; 95% confidence interval 0.71-2.49; P = 0.4) and high-risk patients (hazard ratio 1.03; 95% confidence interval 0.45-2.34; P = 0.9). Virtually the same results were recorded in inverse probability treatment weighting cohorts. CONCLUSIONS Relying on a large cohort of EBRT-treated intermediate- and high-risk patients, no BCR differences were recorded between trial participants and non-participants after accounting for confounders.
Collapse
Affiliation(s)
- R S Flammia
- Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy; Cancer Prognostics and Health Outcomes Unit, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - D Lavigne
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.
| | - Z Tian
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - F Saad
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada; Department of Surgery, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - U Anceschi
- Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy; Department of Uro-oncology, National Cancer Institute, IRCCS "IFO-Reginal Elena", Rome, Italy
| | - M Gallucci
- Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
| | - C Leonardo
- Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
| | - F Preisser
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
| | - P Mandel
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
| | - F K H Chun
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - G Delouya
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - D Taussky
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada
| | - B Hoeh
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
| |
Collapse
|
3
|
von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, Yanagisawa T, Kawada T, Karakiewicz PI, Gontero P, Pradere B, Ploussard G, Rink M, Shariat SF. The current role of precision surgery in oligometastatic prostate cancer. ESMO Open 2022; 7:100597. [PMID: 36208497 PMCID: PMC9551071 DOI: 10.1016/j.esmoop.2022.100597] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 08/31/2022] [Accepted: 09/07/2022] [Indexed: 12/30/2022] Open
Abstract
Oligometastatic prostate cancer (omPCa) is a novel intermediate disease state characterized by a limited volume of metastatic cells and specific locations. Accurate staging is paramount to unmask oligometastatic disease, as provided by prostate-specific membrane antigen-positron emission tomography. Driven by the results of prospective trials employing conventional and/or modern staging modalities, the treatment landscape of omPCa has rapidly evolved over the last years. Several treatment-related questions comprising the concept of precision strikes are under development. For example, beyond systemic therapy, cohort studies have found that cytoreductive radical prostatectomy (CRP) can confer a survival benefit in select patients with omPCa. More importantly, CRP has been consistently shown to improve long-term local symptoms when the tumor progresses across disease states due to resistance to systemic therapies. Metastasis-directed treatments have also emerged as a promising treatment option due to the visibility of oligometastatic disease and new technologies as well as treatment strategies to target the novel PCa colonies. Whether metastases are present at primary cancer diagnosis or detected upon biochemical recurrence after treatment with curative intent, targeted yet decisive elimination of disseminated tumor cell hotspots is thought to improve survival outcomes. One such strategy is salvage lymph node dissection in oligorecurrent PCa which can alter the natural history of progressive PCa. In this review, we will highlight how refinements in modern staging modalities change the classification and treatment of (oligo-)metastatic PCa. Further, we will also discuss the current role and future directions of precision surgery in omPCa.
Collapse
Affiliation(s)
- M von Deimling
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Rajwa
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
| | - D Tilki
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - A Heidenreich
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Cologne, Cologne, Germany
| | - M Pallauf
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Bianchi
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - T Yanagisawa
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
| | - T Kawada
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
| | - P Gontero
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
| | - B Pradere
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France
| | - G Ploussard
- Department of Urology, La Croix Du Sud Hospital, Quint-Fonsegrives, France
| | - M Rink
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
| |
Collapse
|
4
|
Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, Briganti A, Scherr DS, Shariat SF. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 2016; 19:163-7. [PMID: 26810014 DOI: 10.1038/pcan.2015.60] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 09/11/2015] [Accepted: 10/07/2015] [Indexed: 12/17/2022]
Abstract
BACKGROUND To assess the prognostic value of preoperative C-reactive protein (CRP) serum levels for prognostication of biochemical recurrence (BCR) after radical prostatectomy (RP) in a large multi-institutional cohort. METHODS Data from 7205 patients treated with RP at five institutions for clinically localized prostate cancer (PCa) were retrospectively analyzed. Preoperative serum levels of CRP within 24 h before surgery were evaluated. A CRP level ⩾0.5 mg dl(-1) was considered elevated. Associations of elevated CRP with BCR were evaluated using univariable and multivariable Cox proportional hazards regression models. Harrel's C-index was used to assess prognostic accuracy (PA). RESULTS Patients with higher Gleason score on biopsy and RP, extracapsular extension, seminal vesicle invasion, lymph node metastasis, and positive surgical margins status had a significantly elevated preoperative CRP compared to those without these features. Patients with elevated CRP had a lower 5-year BCR survival proportion as compared to those with normal CRP (55% vs 76%, respectively, P<0.0001). In pre- and postoperative multivariable models that adjusted for standard clinical and pathologic features, elevated CRP was independently associated with BCR (P<0.001). However, the addition of preoperative CRP did not improve the accuracy of the standard pre- and postoperative models for prediction of BCR (70.9% vs 71% and 78.9% vs 78.7%, respectively). CONCLUSIONS Preoperative CRP is elevated in patients with pathological features of aggressive PCa and BCR after RP. While CRP has independent prognostic value, it does not add prognostically or clinically significant information to standard predictors of outcomes.
Collapse
Affiliation(s)
- S Sevcenco
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria
| | - R Mathieu
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.,Department of Urology, Rennes University Hospital, Rennes, France
| | - P Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - T Klatte
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria
| | - H Fajkovic
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria
| | - C Seitz
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
| | - M Rouprêt
- Academic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France
| | - M Rink
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Kluth
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Q-D Trinh
- School of Medicine, Sacramento, CA, USA.,Department of Surgery, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - W Loidl
- Department of Urology, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
| | - A Briganti
- Urological Research Institute, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
| | - D S Scherr
- Department of Urology, Weill Cornell Medical College, New York, NY, USA
| | - S F Shariat
- Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.,Department of Urology, Weill Cornell Medical College, New York, NY, USA.,Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
| |
Collapse
|
5
|
Schiffmann J, Haese A, Leyh-Bannurah SR, Salomon G, Steuber T, Schlomm T, Boehm K, Beyer B, Larcher A, Michl U, Heinzer H, Huland H, Graefen M, Karakiewicz PI. Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. Eur J Surg Oncol 2015; 41:1547-53. [PMID: 26117216 DOI: 10.1016/j.ejso.2015.05.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 04/01/2015] [Accepted: 05/19/2015] [Indexed: 10/23/2022] Open
Abstract
PURPOSE Contemporary adherence of the indication to European Association of Urology (EAU) guideline recommendation for pelvic lymph node dissection (PLND) at either open (ORP) or robot-assisted radical prostatectomy (RARP) at a high-volume center is unknown. To assess guideline recommended and observed PLND rates in a high-volume center cohort. METHODS We relied on the Martini-Clinic database and focused on patients treated with either ORP or RARP, between 2010 and 2013. Actual performed PLND was compared to European Association of Urology (EAU) guideline recommendation defined by nomogram predicted risk of lymph node invasion >5%. Categorical and multivariable logistic regression analyses targeted two endpoints: 1) probability of guideline recommended PLND and 2) probability of no PLND, when not recommended by EAU guideline. RESULTS Within 7868 PCa patients, adherence to EAU PLND guideline recommendation was 97.1% at ORP and 96.8% at RARP (p = 0.7). When PLND was not recommended, it was more frequently performed at RARP (71.6%) than at ORP (66.2%) (p = 0.002). Gleason score, PSA and number of positive biopsy cores were independent predictors for both either PLND when recommended, or no PLND when not recommended (all p < 0.05). Clinical tumor stage, age and surgical approach were also independent predictors for no PLND when not recommended (all p < 0.05). CONCLUSIONS Adherence of the indication to EAU guideline recommended PLND is high at this high-volume center. Neither ORP nor RARP represent a barrier for PLND, when recommended. However, a high number of patients underwent PLND despite absence of guideline recommendation. Possible staging advantages and PLND related complications needs to be individually considered, especially, when LNI risk is low.
Collapse
Affiliation(s)
- J Schiffmann
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
| | - A Haese
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - G Salomon
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Steuber
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Schlomm
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Boehm
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - B Beyer
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Larcher
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
| | - U Michl
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Heinzer
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Huland
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Graefen
- Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada
| |
Collapse
|
6
|
Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 2014; 40:1738-45. [PMID: 25454826 DOI: 10.1016/j.ejso.2014.10.004] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2014] [Revised: 09/28/2014] [Accepted: 10/06/2014] [Indexed: 11/26/2022] Open
Abstract
INTRODUCTION Existing radical cystectomy (RC) perioperative mortality estimates may underestimate the contemporary rates due to more advanced age, more baseline comorbidities and potentially broader inclusion criteria for RC, relative to past criteria. METHODS Within the most recent Surveillance, Epidemiology, and End Results (SEER)-Medicare database we identified clinically non-metastatic, muscle-invasive (T2-T4a) urothelial carcinoma of the urinary bladder (UCUB) patients, who underwent RC between 1991 and 2009. Mortality at 30- and 90-day after RC was quantified. Multivariable logistic regression analyses tested predictors of 90-day mortality. RESULTS Within 5207 assessable RC patients 30- and 90-day mortality rates were 5.2 and 10.6%, respectively. According to age 65-69, 70-79 and ≥ 80 years, 90-day mortality rates were 6.4, 10.1 and 14.8% (p < 0.001). Additionally, 90-day mortality rates increased with increasing Charlson Comorbidity Index (CCI, 0, 1, 2 and ≥ 3): 6.3, 10.3, 12.6 and 15.9% (p < 0.001). 90-day mortality rate in unmarried patients was 13.0 vs. 9.3% in married individuals (p < 0.001). In multivariable logistic regression analyses, advanced age, higher CCI, low socioeconomic status, unmarried status and non organ-confined stage were independent predictors of 90-day mortality (all p < 0.05). CONCLUSIONS The contemporary SEER-Medicare derived 90-day mortality rates are substantially higher than previously reported estimates from centers of excellence, and even exceed previous SEER reports. More advanced age, higher CCI score, and other patient characteristics that distinguish the current population from others account for these differences.
Collapse
Affiliation(s)
- J Schiffmann
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | - G Gandaglia
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
| | - A Larcher
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
| | - M Sun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - Z Tian
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - S F Shariat
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - M McCormack
- Department of Urology, University of Montreal Health Center, Montreal, Canada
| | - L Valiquette
- Department of Urology, University of Montreal Health Center, Montreal, Canada
| | - F Montorsi
- Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy
| | - M Graefen
- Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Saad
- Department of Urology, University of Montreal Health Center, Montreal, Canada
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada
| |
Collapse
|
7
|
Gandaglia G, Karakiewicz PI, Briganti A, Menon M, Sun M, Abdollah F. In reply to the letter to the editor 'in Reply to Gandaglia et al.' by De Bari et al. Ann Oncol 2014; 25:1862-1863. [PMID: 24914042 DOI: 10.1093/annonc/mdu215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G Gandaglia
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - A Briganti
- Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
| | - M Menon
- Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Detroit, USA
| | - M Sun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada
| | - F Abdollah
- Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Detroit, USA.
| |
Collapse
|
8
|
Gandaglia G, Karakiewicz PI, Abdollah F, Becker A, Roghmann F, Sammon JD, Kim SP, Perrotte P, Briganti A, Montorsi F, Trinh QD, Sun M. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis. Eur J Surg Oncol 2014; 40:1706-15. [PMID: 24915856 DOI: 10.1016/j.ejso.2014.05.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 04/28/2014] [Accepted: 05/04/2014] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVE To evaluate the effect of advancing age on cancer-specific mortality (CSM) after radical prostatectomy (RP). MATERIALS AND METHODS Overall, 205,551 patients with PCa diagnosed between 1988 and 2009 within the Surveillance Epidemiology and End Results (SEER) database were included in the study. Patients were stratified according to age at diagnosis: ≤ 50, 51-60, 61-70, and ≥ 71 years. The 15-year cumulative incidence CSM rates were computed. Competing-risks regression models were performed to test the effect of age on CSM in the entire cohort, and for each grade (Gleason score 2-4, 5-7, and 8-10) and stage (pT2, pT3a, and pT3b) sub-cohorts. RESULTS Advancing age was associated with higher 15-year CSM rates (2.3 vs. 3.4 vs. 4.6 vs. 6.3% for patients aged ≤ 50 vs. 51-60 vs. 61-70 vs. ≥ 71 years, respectively; P < 0.001). In multivariable analyses, age at diagnosis was a significant predictor of CSM. This relationship was also observed in sub-analyses focusing on patients with Gleason score 5-7, and/or pT2 disease (all P ≤ 0.05). Conversely, age failed to reach the independent predictor status in men with Gleason score 2-4, 8-10, pT3a, and/or pT3b disease. CONCLUSIONS Advancing age increases the risk of CSM. However, when considering patients affected by more aggressive disease, age was not significantly associated with higher risk of dying from PCa. In high-risk patients, tumor characteristics rather than age should be considered when making treatment decisions.
Collapse
Affiliation(s)
- G Gandaglia
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
| | - P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
| | - F Abdollah
- Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
| | - A Becker
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Martiniclinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Roghmann
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Department of Urology, Ruhr-University Bochum, Germany
| | - J D Sammon
- Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA
| | - S P Kim
- Department of Urology, Mayo Clinic, Rochester, NY, USA
| | - P Perrotte
- Department of Urology, University of Montreal Health Centre, Montreal, Canada
| | - A Briganti
- Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
| | - F Montorsi
- Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Q-D Trinh
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Department of Surgery, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M Sun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
| |
Collapse
|
9
|
Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Kautzky-Willer A, Bachmann A, Shariat SF. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 2013; 40:113-20. [PMID: 24113620 DOI: 10.1016/j.ejso.2013.09.016] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Revised: 09/04/2013] [Accepted: 09/10/2013] [Indexed: 12/16/2022] Open
Abstract
AIMS Evidence suggests a detrimental effect of diabetes mellitus (DM) on cancer incidence and outcomes. To date, the effect of DM and its treatment on prognosis in upper tract urothelial carcinoma (UTUC) remains uninvestigated. We tested the hypothesis that DM and metformin use impact oncologic outcomes of patients treated with radical nephroureterectomy (RNU) for UTUC. METHODS Retrospective analysis of 2492 patients with UTUC treated at 23 institutions with RNU without neoadjuvant therapy. Cox regression models addressed the association of DM and metformin use with disease recurrence, cancer-specific mortality and any-cause mortality. RESULTS A total of 365 (14.3%) patients had DM and 194 (7.8%) patients used metformin. Within a median follow-up of 36 months, 663 (26.6%) patients experienced disease recurrence, 545 patients (21.9%) died of UTUC and 884 (35.5%) patients died from any cause. Diabetic patients who did not use metformin were at significantly higher risk of disease recurrence and cancer-specific death compared to non-diabetic patients and diabetic patients who used metformin. In multivariable Cox regression analyses, DM treated without metformin was associated with worse recurrence-free survival (HR: 1.44, 95% CI 1.10-1.90, p = 0.009) and cancer-specific mortality (HR: 1.49, 95% CI 1.11-2.00, p = 0.008). CONCLUSIONS Diabetic UTUC patients without metformin use have significantly worse oncologic outcomes than diabetics who used metformin and non-diabetics. The possible mechanism behind the impact of DM on UTUC biology and the potentially protective effect of metformin need further elucidation.
Collapse
Affiliation(s)
- M Rieken
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA; Department of Urology, University Hospital Basel, Basel, Switzerland
| | - E Xylinas
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | - L Kluth
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Q-D Trinh
- Division of Urologic Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - R K Lee
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA
| | - H Fajkovic
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - G Novara
- Department of Surgical, Oncological and Gastroenterologic Sciences, Urology Clinic, University of Padua, Italy
| | - V Margulis
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Y Lotan
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - J I Martinez-Salamanca
- Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain
| | - K Matsumoto
- Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
| | - C Seitz
- Department of Urology, Medical University of Vienna, Vienna, Austria
| | - M Remzi
- Department of Urology, Landesklinikum Korneuburg, Korneuburg, Austria
| | - P I Karakiewicz
- Department of Urology, University of Montreal, Montreal, QC, Canada
| | - D S Scherr
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA
| | - A Briganti
- Department of Urology, Vita-Salute University, Milan, Italy
| | - A Kautzky-Willer
- Unit of Gender Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - A Bachmann
- Department of Urology, University Hospital Basel, Basel, Switzerland
| | - S F Shariat
- Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA; Department of Urology, Medical University of Vienna, Vienna, Austria.
| | | |
Collapse
|
10
|
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013; 109:1460-6. [PMID: 23982601 PMCID: PMC3776972 DOI: 10.1038/bjc.2013.372] [Citation(s) in RCA: 168] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Revised: 06/13/2013] [Accepted: 06/22/2013] [Indexed: 11/24/2022] Open
Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) risk tables and the Spanish Urological Club for Oncological Treatment (CUETO) scoring model are the two best-established predictive tools to help decision making for patients with non-muscle-invasive bladder cancer (NMIBC). The aim of the current study was to assess the performance of these predictive tools in a large multicentre cohort of NMIBC patients. Methods: We performed a retrospective analysis of 4689 patients with NMIBC. To evaluate the discrimination of the models, we created Cox proportional hazard regression models for time to disease recurrence and progression. We incorporated the patients calculated risk score as a predictor into both of these models and then calculated their discrimination (concordance indexes). We compared the concordance index of our models with the concordance index reported for the models. Results: With a median follow-up of 57 months, 2110 patients experienced disease recurrence and 591 patients experienced disease progression. Both tools exhibited a poor discrimination for disease recurrence and progression (0.597 and 0.662, and 0.523 and 0.616, respectively, for the EORTC and CUETO models). The EORTC tables overestimated the risk of disease recurrence and progression in high-risk patients. The discrimination of the EORTC tables was even lower in the subgroup of patients treated with BCG (0.554 and 0.576 for disease recurrence and progression, respectively). Conversely, the discrimination of the CUETO model increased in BCG-treated patients (0.597 and 0.645 for disease recurrence and progression, respectively). However, both models overestimated the risk of disease progression in high-risk patients. Conclusion: The EORTC risk tables and the CUETO scoring system exhibit a poor discrimination for both disease recurrence and progression in NMIBC patients. These models overestimated the risk of disease recurrence and progression in high-risk patients. These overestimations remained in BCG-treated patients, especially for the EORTC tables. These results underline the need for improving our current predictive tools. However, our study is limited by its retrospective and multi-institutional design.
Collapse
Affiliation(s)
- E Xylinas
- 1] Department of Urology, Weill Cornell Medical College, New York, NY, USA [2] Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 2013; 107:1826-32. [PMID: 23169335 PMCID: PMC3504939 DOI: 10.1038/bjc.2012.464] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND In pT1-T3N0 urothelial carcinoma of the bladder (UCB) patients, multi-modal therapy is inconsistently recommended. The aim of the study was to develop a prognostic tool to help decision-making regarding adjuvant therapy. METHODS We included 2145 patients with pT1-3N0 UCB after radical cystectomy (RC), naive of neoadjuvant or adjuvant therapy. The cohort was randomly split into development cohort based on the US patients (n=1067) and validation cohort based on the Europe patients (n=1078). Predictive accuracy was quantified using the concordance index. RESULTS With a median follow-up of 45 months, 5-year recurrence-free and cancer-specific survival estimates were 68% and 73%, respectively. pT-stage, ge, lymphovascular invasion, and positive margin were significantly associated with both disease recurrence and cancer-specific mortality (P-values ≤ 0.005). The accuracies of the multivariable models at 2, 5, and 7 years for predicting disease recurrence were 67.4%, 65%, and 64.4%, respectively. Accuracies at 2, 5, and 7 years for predicting cancer-specific mortality were 69.3%, 66.4%, and 65.5%, respectively. We developed competing-risk, conditional probability nomograms. External validation revealed minor overestimation. CONCLUSION Despite RC, a significant number of patients with pT1-3N0 UCB experience disease recurrence and ultimately die of UCB. We developed and externally validated competing-risk, conditional probability post-RC nomograms for prediction of disease recurrence and cancer-specific mortality.
Collapse
Affiliation(s)
- E Xylinas
- Department of Urology, Weill Cornell Medical College, Starr 900, 525 East 68th Street, Box 94, New York, NY 10065, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Rink M, Chun FKH, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, Shariat SF. Tissue-based molecular markers for renal cell carcinoma. MINERVA UROL NEFROL 2011; 63:293-308. [PMID: 21996985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-α), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.
Collapse
Affiliation(s)
- M Rink
- Department of Urology, University of Hamburg, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2011; 23:973-80. [PMID: 21890909 DOI: 10.1093/annonc/mdr362] [Citation(s) in RCA: 429] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND We assessed the distribution of site-specific metastases in patients with renal cell carcinoma (RCC) according to age. Moreover, we evaluated recommendations proposed by guidelines and focused specifically on bone and brain metastases. PATIENTS AND METHODS Patients with metastatic RCC (mRCC) were abstracted from the Nationwide Inpatient Sample (1998-2007). Age was stratified into four groups: <55, 55-64, 65-74 and ≥ 75 years. Cochran-Armitage trend test and multivariable logistic regression analysis tested the relationship between age and the rate of multiple metastatic sites. Finally, we examined the rates of brain or bone metastases according to the presence of other metastatic sites. RESULTS In 11,157 mRCC patients, the rate of multiple metastatic sites decreased with increasing age (P < 0.001). This phenomenon was confirmed in patients with lung, bone, liver and brain metastases (all P ≤ 0.01). The rate of bone metastases was 10% in patients with exclusive abdominal metastases and 49% in patients with abdominal, thoracic and brain metastases. The rate of brain metastases was 2% in patients with exclusive abdominal metastases and 16% in patients with thoracic and bone metastases. CONCLUSIONS The proportion of patients with multiple metastatic sites is higher in young patients. The rates of bone (10%-49%) and brain (2%-16%) metastases are nonnegligible in mRCC patients.
Collapse
Affiliation(s)
- M Bianchi
- Department of Urology, Vita-Salute University, Urological Research Institute, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Budäus L, Morgan M, Abdollah F, Zorn KC, Sun M, Johal R, Thuret R, Abdo A, Schmitges J, Isbarn H, Jeldres C, Perrotte P, Graefen M, Karakiewicz PI. Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: a population-based study. Eur J Surg Oncol 2011; 37:429-34. [PMID: 21492776 DOI: 10.1016/j.ejso.2011.02.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2010] [Revised: 01/29/2011] [Accepted: 02/28/2011] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND On average, patients remain hospitalized no more than 2 days after MIRP. The aim of our study was to examine the temporal trends in length of stay ≥ 3 days and to test the relationship between annual surgical volume (ASV) and annual hospital volume (AHV) and length of stay ≥ 3 days in patients undergoing MIRP. MATERIAL AND METHODS Within the Florida Hospital Inpatient Datafile, 2439 men who were treated with MIRP for prostate cancer between 2005 and 2008 were identified. Temporal trends were assessed and uni and multi-variable logistic regression models tested the relationship between ASV, AHV and length of stay ≥ 3 days. RESULTS The average length of stay decreased from 2.4 in 2005 to 1.7 days in 2008. Length of stay ≥ 3 days was recorded in 13.6% of patients and the proportion of patients staying more than ≥ 3 days decreased over time (25.5-12.2%; Chi Square trend p < 0.001). After stratification into low (<1-15 MIRPs) vs. intermediate (16-63 MIRPs) vs. high ASV tertiles (≥ 64 MIRPs) the proportion of patients with length of stay ≥ 3 days were 29.1; 13.2 and 11.1%. In multivariable logistic regression models predicting length of stay ≥ 3 days, ASV, year of surgery and comorbidities achieved independent predictor status and MIRP patients operated by highest ASV tertile surgeons were 71% (p < 0.001) less likely to be hospitalized for more than 3 days. CONCLUSION The length of stay after MIRP decreased between 2005 and 2008. Surgical expertise represented one of the main determinants of shorter length of stay.
Collapse
Affiliation(s)
- L Budäus
- Martiniclinic, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abdollah F, Sun M, Shariat SF, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 national comprehensive cancer network practice guidelines for bladder cancer treatment. Int Braz J Urol 2011. [DOI: 10.1590/s1677-55382011000300029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- F Abdollah
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - M Sun
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - SF Shariat
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - J Schmitges
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - O Djahangirian
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - Z Tian
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - C Jeldres
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - P Perrotte
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | - F Montorsi
- Cancer Prognostics and Health Outcomes Unit, Canada; Vita Salute San Raffaele University, Italy
| | | |
Collapse
|
16
|
Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JH, Lee S, Larkin JMG, Bono P, Rha SY, Castellano DE, Blank CU, Knox JJ, Hawkins R, Yuan RR, Rosamilia M, Booth JL, Bodrogi I. Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Chromecki TF, Svatek RS, Holmäng S, Karakiewicz PI, Mazumdar M, Dunning A, Kamat AM, Tagawa ST, Scherr D, Shariat SF. Prognostic factors of cancer recurrence and progression in non-muscle-invasive urothelial carcinoma: A multicenter study of over 4,300 patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
249 Background: The outcomes of patients with non-muscle-invasive urothelial carcinoma of the bladder (NMIUCB) remain poorly understood. The aim of our study was to identify prognostic factors of cancer recurrence and progression in patients with primary UCB. Methods: We performed a combined analysis on individual data from 4,325 patients with primary NMIUCB. Results: Within a median follow-up of 64 months, 1,960 patients (45.4%) experienced disease recurrence, 498 (11.5%) experienced progression to muscle-invasive stage, 1,155 (26.7%) died of any cause, and 310 (7.2%) died of their cancer. In multivariable Cox regression analysis, advanced age, higher grade, larger tumor size, higher number of tumors, number of prior recurrences, and type of intravesical therapy were independent predictors of disease recurrence and progression. While treatment intravesical chemotherapy was only associated with decreased/delayed cancer recurrence, intravesical BCG therapy was associated with decreased/delayed cancer recurrence and progression. The predictive accuracies of the models for recurrence and progression were 63.5% and 71.3%, respectively. Conclusions: Even in a heterogenous patient population, BCG therapy appears to decrease frequency and delay time to cancer recurrence and progression in patients with NMIUCB. Predictive tools based on combination of multiple clinical variables which capture the biological and clinical potential of nonmuscle-invasive disease could help with patient counseling and individualized risk assessment for adjuvant intravesical therapy and clinical trial design. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. F. Chromecki
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - R. S. Svatek
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. Holmäng
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - P. I. Karakiewicz
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - M. Mazumdar
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - A. Dunning
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - A. M. Kamat
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. T. Tagawa
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - D. Scherr
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| | - S. F. Shariat
- Weill Cornell Medical College, New York, NY; University of Texas M. D. Anderson Cancer Center, Houston, TX; Sahlgrenska University Hospital, Goteborg, Sweden; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
| |
Collapse
|
18
|
Grunwald V, Bodrogi I, Miller K, Machiels JH, Lee S, Chowdhury S, Yuan R, Rosamilia M, Booth JL, Karakiewicz PI. Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
314 Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus is the first agent to show efficacy in a randomized, controlled phase III trial in patients with mRCC after progression on VEGFr-TKIs (RECORD-1). Progression-free survival (PFS) was significantly improved (4.9 vs 1.9 months) and the risk of disease progression was reduced by 67% with everolimus compared with placebo. To fulfill an unmet medical need, everolimus was offered globally in this EAP. Presented here are preliminary results on 605 patients. Methods: The program began in July 2008 (ClinicalTrials.gov: NCT00655252 ; EudraCT: 2007-005460-28), and since then over 1,000 patients in 34 countries have been enrolled. Patients with clear cell and non–clear cell mRCC who failed or became intolerant of VEGFr-TKIs received daily oral doses of everolimus with investigator assessment every 3 months. Results: Data were collected for 605 patients who had discontinued treatment as of January 15, 2010. Evaluable patients had a mean age of 63 years, and most (94%) had progressed after prior VEGFr-TKI therapy. The adverse event (AE) profile did not differ significantly from that reported in the RECORD-1 trial. Most frequently reported grade 3–4 AEs were anemia (6.1%), stomatitis (4.6%), fatigue (4.6%), hyperglycemia (4.0%), and infection (3.6%). Grade 3–4 noninfectious pneumonitis was reported in 2.8%. Best overall response was stable disease, which was evident in 42% of patients. Conclusions: The EAP has allowed patients with mRCC access to everolimus before marketing approval. The rapid enrollment rate of this EAP confirms the unmet medical need after failure of VEGFr-TKIs. Everolimus has shown good tolerability, and no new safety issues have been identified. The investigator-assessed response rate is consistent with that reported in the RECORD-1 trial. The EAP provides an efficient framework for the development of other programs for innovative anticancer agents in patients without satisfactory therapeutic options. [Table: see text]
Collapse
Affiliation(s)
- V. Grunwald
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - I. Bodrogi
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - K. Miller
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - J. H. Machiels
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - S. Lee
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - S. Chowdhury
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - R. Yuan
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - M. Rosamilia
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - J. L. Booth
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| | - P. I. Karakiewicz
- Hannover Medical School, Hannover, Germany; National Institute of Oncology, Budapest, Hungary; Department of Urology, Charité-University Medicine Berlin, Berlin, Germany; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Seoul National University Hospital, Seoul, South Korea; Guy's and St. Thomas' Hospital, London, United Kingdom; Novartis Pharmaceuticals, Florham Park, NJ; University of Medicine and Dentistry of New Jersey, Florham Park, NJ; Novartis Oncology
| |
Collapse
|
19
|
Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. Tissue-based molecular markers for bladder cancer. MINERVA UROL NEFROL 2010; 62:241-258. [PMID: 20940694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Bladder cancer is the second most common genitourinary malignancy in the United States, and is a major cause of morbidity and mortality. Despite aggressive treatment, survival for patients with muscle-invasive urothelial carcinoma of the bladder remains poor. Cancer stage, grade, and other clinical and pathological characteristics provide only limited prognostic information, and there is significant heterogeneity in patient outcomes using current risk stratification. Recent research into the profiling of bladder cancer at the molecular level has begun to shed light on important mechanisms of pathogenesis, as well as providing a number of potential tissue markers. These may provide useful prognostic information and guide patient selection for therapeutic strategies. This review explores recent advances in tissue-based molecular markers in bladder cancer and their potential utility. We also discuss design and statistical consideration for development and validation of molecular markers. A combination of complementary and yet independent molecular markers will likely better capture the biologic potential of each individual bladder tumor resulting in improved clinical decision-making.
Collapse
Affiliation(s)
- C E Barbieri
- Department of Urology, Weill Cornell Medical Center, New York, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Sonpavde G, Khan MM, Lerner SP, Svatek RS, Skinner EC, Karakiewicz PI, Kassouf W, Dinney CP, Fradet Y, Shariat SF. Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Hellenthal N, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Koppie TM. Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5075 Background: There is relatively little literature regarding the use of adjuvant chemotherapy following radical nephroureterectomy in the management of patients with upper tract urothelial carcinoma (UTUC). Our goal was to determine the incidence of receipt of adjuvant chemotherapy in high-risk patients and the ensuing effect on overall- and cancer-specific survival. Methods: Using an international collaborative database, we identified 1390 patients who underwent nephroureterectomy for non-metastatic UTUC between the years of 1992 and 2006. Of these, 542 (39%) patients were classified as high-risk (pT3N0, pT4N0, and/or lymph node positive). These patients were separated into two groups—those who did and did not receive adjuvant chemotherapy—and were stratified by gender, age group, performance status, tumor grade and stage. Cox proportional hazard modeling and Kaplan-Meier analyses were used to determine overall- and cancer-specific survival amongst the cohorts. Results: Of the high-risk patients, 121 (22%) received adjuvant chemotherapy. Adjuvant chemotherapy was more commonly administered in the context of increased tumor grade and stage (p < 0.001). Median survival in the entire cohort was 24 months (range 0–231 months). There was no significant difference in overall- or cancer-specific survival between those who did and did not receive adjuvant chemotherapy; however age, performance status, tumor grade, and tumor stage were significant predictors of both overall and cancer-specific survival. Conclusions: Adjuvant chemotherapy is infrequently utilized in the treatment of patients with high-risk UTUC after nephroureterectomy. Despite this, it appears that adjuvant chemotherapy confers minimal impact on overall- or cancer-specific survival in this group. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Hellenthal
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - S. F. Shariat
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - V. Margulis
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - P. I. Karakiewicz
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - M. Roscigno
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - C. Bolenz
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - M. Remzi
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - A. Weizer
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - R. Zigeuner
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | - T. M. Koppie
- University of California, Davis, Sacramento, CA; University of Texas Southwestern, Dallas, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Montreal, Montreal, QC, Canada; Vita-Salute University, Milan, Italy; Universitatsklinikum Mannheim, Mannheim, Germany; University of Vienna, Vienna, Austria; University of Michigan, Ann Arbor, MI; Medical University Graz, Graz, Austria
| | | |
Collapse
|
22
|
Isbarn H, Sonpavde G, Shariat SF, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Karakiewicz PI. Residual pathologic stage at radical cystectomy and risk stratification of patients with pT2N0 bladder cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5076 Background: We hypothesized that in patients with pT2N0 transitional cell carcinoma (TCC) of the urinary bladder, residual muscle-invasive disease at radical cystectomy (RC) may confer poorer outcomes than residual non-muscle invasive disease due to larger tumor volume and/or biologically more aggressive disease. Patients with high-risk pT2N0 disease may be candidates for trials of adjuvant therapy. Methods: Patients from the BCRC database with pT2N0 stage (N = 208) at TUR (transurethral resection) whose tumors were organ-confined at RC (≤pT2N0) were analyzed. T1N0 patients (N=33) with pT2 disease at RC were also examined in order to include all pT2 patients. None of the patients had received perioperative chemotherapy. The effect of residual pT-stage at RC on outcomes was evaluated in Kaplan-Meier, as well as in univariable and multivariable Cox-regression models. Covariates consisted of age, gender, grade, lymphovascular invasion, concomitant carcinoma-in-situ (CIS), number of lymph nodes removed, and the year of surgery. Results: Among baseline T2N0 patients, residual pT-stage at RC was pT0 in 24 (11.5%), pTa in 9 (4.3%), pCIS in 22 (10.6%), pT1 in 35 (16.8%), and pT2 in 118 patients (56.7%). The median follow-up was 50.1 months. The 5-year recurrence-free survivals of patients with residual pT0/pTa/pCis, pT1 and pT2 were 100%, 85% and 75%, respectively. The 5-year cancer-specific survival rates for the same patient cohorts were 100%, 93%, and 81%, respectively. In multivariable analyses, the effect of residual stage <pT2 at RC achieved independent predictor status for recurrence (adjusted HR 0.20; p = 0.002), as well as for cancer-specific survival (adjusted HR: 0.24; p = 0.02). Initial T1 patients who were pT2 at RC did not have statistically different outcomes compared to initial T2 followed by pT2 at RC. Conclusions: Patients with pT2N0 TCC of the urinary bladder with residual non-muscle invasive disease at RC have significantly better long-term outcomes compared to residual muscle-invasive disease. With further validation, these data may facilitate the risk-stratification of patients with pT2N0 disease and enable the selection of high-risk patients for trials of adjuvant therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Isbarn
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - G. Sonpavde
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - S. F. Shariat
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - G. S. Palapattu
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - A. I. Sagalowsky
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - Y. Lotan
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - M. P. Schoenberg
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - G. E. Amiel
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - S. P. Lerner
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| | - P. I. Karakiewicz
- University of Montreal, Montreal, QC, Canada; Texas Oncology, Baylor College of Medicine, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Rochester, Rochester, NY; University of Texas Southwestern, Dallas, TX; Johns Hopkins Hospital, Baltimore, MD; Baylor College of Medicine, Houston, TX
| |
Collapse
|
23
|
Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Muller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF. Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. J Natl Cancer Inst 2009; 101:114-9. [DOI: 10.1093/jnci/djn451] [Citation(s) in RCA: 120] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Lessard L, Bégin LR, Schlomm T, Köllermann J, Graefen M, Karakiewicz PI, Mes-Masson A, Saad F. Validation of NF-kappaB p65 as a prostate cancer prognostic marker on a large cohort of European patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Koumakpayi I, Le Page C, Karakiewicz PI, Diallo J, Lessard L, Mes-Masson A, Saad F. Gamma-Secretase, ErbB4 nuclear localization and neuregulin expression correlates with prostate cancer patient clinical outcome. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10587 Background: Membrane protein ErbB4 is a member of ErbB growth factor receptor family, which can be activated by neuregulins (NRG). Upon neuregulin activation, ErbB4 is cleaved within its transmembrane domain by presenilin γ-secratase (PSN) to release an intracellular domain that translocates into the nucleus. Although, ErbB4 ligand-dependant translocation of ErbB4 to the nucleus and its nuclear activity has been reported in breast cancer cell lines, there are few reports concerning ErbB4 nuclear localization and its clinical relevance. Here, we report for the first time the clinical relevance of ErbB4 nuclear localization, NRG, and PSN expression in prostate cancer tissues. Methods: Immunostaining using anti-ErbB4, anti-PSN2 and anti-neuregulin antibodies was done on a set of tissue microarrays (TMA) from 140 patients. The TMAs contained, 92 cores of normal prostate tissue obtained from 46 autopsy specimens from young males, 373 tumor and normal adjacent cores from 63 hormone sensitive PCa (HSPCa) patients, and 146 cores from 31 hormone refractory PCa (HRPCa) patients. Results: We found a statistically significant increase (p<0.01) in the percentage of ErbB4 nuclear localization (68.7% vs 53.2%), NRG expression (2.06 vs 1.41) and PSN2 expression (2.14 vs 1.53) when comparing cancerous tissues to normal tissue adjacent to cancer. Interestingly, a similar statistically significant increase in nuclear ErbB4 and NRG expression was observed when comparing HRPCa to HSPCa (p<0.001). In cancerous tissues, a strong correlation was found between nuclear ErbB4 and NRG expression (r=0.672), between nuclear ErbB4 and PSN2 expression (r=0.51), and between PSN2 and NRG expression (r=0.71). Nuclear ErbB4 and PSN2 inversely correlated with tumor stage and lymph node invasion. Kaplan Meier analysis of nuclear ErbB4 (p=0.030) and PSN2 expression (p=0.018) showed an inverse association with biochemical recurrence (BCR) of PCa. In multivariate analyses including these three markers and clinical parameters, only nuclear ErbB4 retained an independent prognosis value. Conclusion: Our results suggest that high nuclear ErbB4 along with increased PSN2 expression have a protective effect against prostate cancer progression and BCR. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Koumakpayi
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - C. Le Page
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - P. I. Karakiewicz
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - J. Diallo
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - L. Lessard
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - A. Mes-Masson
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| | - F. Saad
- CRCHUM Hopital Notre Dame, Montreal, PQ, Canada; Universite de Montreal, Montreal, PQ, Canada
| |
Collapse
|
26
|
Pantuck AJ, Trinh Q, Karakiewicz PI, Fergelot P, Rioux-Leclercq N, Figlin R, Said J, Belldegrun A, Patard J. Use of carbonic anhydrase IX (CAIX) expression and Von Hippel Lindau (VHL) gene mutation status to predict survival in renal cell carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5042 Background: VHL gene mutations induce the expression of CAIX, and previous studies have shown that low CAIX results in worse prognosis for RCC. We attempt to further describe the relationship between CAIX expression, VHL gene mutations and tumor characteristics. Methods: Radical nephrectomy was performed in 100 patients at 2 centers. Genomic DNA was extracted from frozen tumor samples using the QIAmp DNA mini kit. Four amplimers covering the whole coding sequence of the VHL gene were synthesized by PCR and sequenced by Big Dye. Mutation bearing sequences were confirmed by a second round of sequencing. The monoclonal antibody M75 was used to score the expression of the CAIX protein. Life table, Kaplan-Meier and Cox regression analyses addressed RCC-specific mortality (RCC-SM). Results: VHL mutations were identified in 58 patients (58%) and CAIX tumor expression ranged from 0% to 100%. Low CAIX expression (<85%) was associated with absence of VHL mutation (p=0.02), larger tumors (p=0.002), higher T stage (p=0.007), nodal metastases (p=0.001) and higher Fuhrman grade (p=0.006). Absence of VHL mutation was associated with worse ECOG (p=0.005), higher T stage (p=0.01) and presence of nodal (p=0.03) and distant metastases (p=0.02). Categorically-coded, CAIX was a statistically significant predictor of RCC-SM (p=0.002), while VHL mutation approached statistical significance (p=0.08) and a trend was observed for worse survival when VHL was not mutated. Patients with both high CAIX and VHL mutation had better survival (95.9% 1 year and 6 year median survival) than their counterparts with low CAIX expression and absence of VHL mutation (62.9% 1 year and 1.5 year median survival) (p<0.001). In Cox regression analyses, neither CAIX (p=0.06) nor VHL (p=0.4) achieved independent predictor status, when adjusted for age, gender, TNM stage, tumor size, Fuhrman and ECOG. Conclusions: Low CAIX expression is associated with the absence of VHL mutation and aggressive tumor characteristics, and is a statistically significant predictor of poor prognosis in patients with clear cell RCC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. J. Pantuck
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - Q. Trinh
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - P. I. Karakiewicz
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - P. Fergelot
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - N. Rioux-Leclercq
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - R. Figlin
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - J. Said
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - A. Belldegrun
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| | - J. Patard
- David Geffen School of Medicine at UCLA, Los Angeles, CA; University of Montreal Health Center, Montreal, PQ, Canada; University of Rennes, Rennes, France
| |
Collapse
|
27
|
Karakiewicz PI, Benayoun S, Bégin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007; 61:425-30. [PMID: 17313610 DOI: 10.1111/j.1742-1241.2006.00905.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Tissue inflammation has been linked to cancer in several disease models. We tested the association between chronic inflammation and prostate cancer (PCa), as well as high-grade prostatic intraepithelial neoplasia (HGPIN), in prostatic needle biopsy specimens. Tissues from 4526 men, who underwent systematic ultrasound-guided sextant needle biopsies of the prostate, were classified in the following order as PCa, or HGPIN, or chronic inflammation or benign. PCa was diagnosed in 1633 (36.1%), HGPIN in 535 (11.8%) and chronic inflammation in 347 (7.7%). Chronic inflammation conferred a protective effect from PCa: odds ratio (OR) = 0.20, 95% confidence interval (CI) = 0.15-0.28. Chronic inflammation was also inversely associated with HGPIN: OR = 0.11, 95% CI = 0.05-0.22. The ORs remained virtually unchanged after adjustment for age, serum prostate-specific antigen (PSA), digital rectal examination (DRE) and gland volume. Chronic inflammation is more frequent in the presence of benign histology than it is in the presence of PCa or HGPIN.
Collapse
Affiliation(s)
- P I Karakiewicz
- Department of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montreal, 1058 rue St-Denis, Montreal, Quebec, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Karakiewicz PI, Perrotte P, Valiquette L, Benard F, McCormack M, Menard C, McNaughton Collins M, Nickel JC. French-Canadian linguistic validation of the NIH Chronic Prostatitis Symptom Index. Can J Urol 2005; 12:2816-23. [PMID: 16274517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
INTRODUCTION The NIH Chronic Prostatitis Symptom Index (CPSI) is recommended in the clinical evaluation of men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). However, its use is not possible in French speakers, as it has not been validated in this population. We performed a linguistic validation of the CPSI. METHODS Linguistic translation followed the forward-backward-forward technique and relied on professional medical translators, bilingual health professionals, and patient input. Along with the SF-12, the translated version was administered to a convenience sample of men presenting for pre-vasectomy visits (controls) and to consecutive patients with established CP/CPPS (cases). Men with CP/CPPS were subsequently asked to complete a 14-day retest questionnaire. Psychometric testing addressed standard reliability and validity characteristics. RESULTS Thirty-six cases and 38 controls with respective mean ages of 46.5 and 44.0 years participated and 33 (91.2%) cases completed the retest questionnaire. Pain (p<0.001), urinary (p<0.001) and quality-of-life (QOL) scale (p<0.001) score means differed between cases and controls. For the same scales, Cronbach's alphas for cases were respectively 0.70, 0.72 and 0.79 versus 0.80, 0.57, and 0.88 for controls. The retest product-moments were 0.83 for pain, 0.55 for urinary, and 0.83 for QOL scales. In cases, strong correlation was noted between QOL and pain scales (r=0.7), and between urinary and pain scales (r=0.6), versus moderate correlation between QOL and urinary scales (r=0.4). Negative correlation was recorded between CPSI scales and SF-12 scales, which ranged from -0.2 to -0.4. CONCLUSIONS When applied to CPPS and control subjects, the French Canadian CPSI translation demonstrates excellent discriminant properties. Moreover, its reliability and validity characteristics confirm the qualities of the CPSI as a standard evaluative tool for men with CPPS.
Collapse
Affiliation(s)
- P I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, Montreal Health Center, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Steuber T, Karakiewicz PI, Augustin H, Erbersdobler A, Lange I, Haese A, Chun KHF, Walz J, Graefen M, Huland H. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol 2005; 173:737-41. [PMID: 15711259 DOI: 10.1097/01.ju.0000152591.33259.f9] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE The Partin tables represent the most widely used predictor of pathological stage in men with localized prostate cancer (PCa). The accuracy and performance of the tables have been tested across different populations. However, to our knowledge the potential limitations that may stem from differences between transition zone (TZ) and peripheral zone (PZ) prostate cancers has not been explored. We tested the predictive accuracy and performance of the Partin tables according to TZ vs PZ tumor predominance. MATERIALS AND METHODS Preoperative serum prostate specific antigen, clinical stage and biopsy Gleason sum data on 1,990 patients treated with radical retropubic prostatectomy were used to define the 2001 Partin probabilities of organ confinement and seminal vesicle invasion (SVI). Data on 1,320 patients who underwent staging pelvic lymphadenectomy and radical retropubic prostatectomy were used to define the probabilities of lymph node invasion (LNI) and organ confined disease (OC). ROC area under the curve was used to assess the predictive accuracy of the 2001 Partin tables relative to observed extracapsular extension (ECE), SVI, LNI and OC. Performance characteristics for each prediction were explored graphically with local regression, nonparametric smoothing plots. Results were compared between 222 TZ cancers and 1,768 PZ cancers. RESULTS The 1,990 radical retropubic prostatectomy specimens demonstrated ECE in 689 cases (34.6%) (TZ in 58 or 27.1% and PZ in 631 or 35.8%) and SVI in 224 (TZ in 13 or 6.1% and PZ in 211 or 11.9%). The 1,320 lymphadenectomy specimens demonstrated LNI in 56 cases (TZ in 2 or 0.9% and PZ in 54 or 4.6%). OC was found in 784 cases (59.4%) (TZ in 95 or 69.9% and PZ in 689 or 58.2%). Predictive accuracy was for ECE 76.4% (TZ 69.0% and PZ 77.2%), 78.0% for SVI (TZ 73.5% and PZ 78.3%), 78.6% for LNI (TZ 44.5% and PZ 79.9%) and 79.4% for OC (TZ 73.8% and PZ 80.0%). CONCLUSIONS The biological tumor characteristics of TZ PCa differ from those of PZ PCa. These differences appear to undermine the accuracy of pathological stage predictions.
Collapse
Affiliation(s)
- T Steuber
- Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino PT, Kattan MW, Huland H. [Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy]. Urologe A 2003; 42:685-92. [PMID: 12750804 DOI: 10.1007/s00120-002-0251-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
In patients suffering from prostate cancer, preoperative nomograms, which predict the risk of recurrence may provide a helpful tool in regard to the counselling and planning of an appropriate therapy. The best known nomograms were published by the Baylor College of Medicine, Houston and the Harvard Medical School, Boston. We investigated these nomograms derived in the U.S. when applied to German patients. Data from 1003 patients who underwent radical prostatectomy at the University-Hospital Hamburg were used for validation. Nomogram predictions of the probability for 2-years (Harvard nomogram) and 5-years (Kattan nomogram) freedom from PSA recurrence were compared with actual follow-up recurrence data using areas under the receiver-operating-characteristic curves (AUC). The recurrence free survival after 2 and 5 years was 78% and 58%, respectively. The AUC of the Harvard nomogram predicting 2-years probability of freedom from PSA recurrence was 0.80 vs. Kattan-Nomogram 5-years prediction of 0.83. Thereby, the Kattan nomogram showed a significant higher predictive accuracy (p=0.0274). For that reason preoperative nomograms derived in the U.S. can be applied to german patients. However, we would recommend the utilization of the Kattan nomogram due to its higher predictive accuracy.
Collapse
Affiliation(s)
- M Graefen
- Klinik und Poliklinik für Urologie, Universitätsklinik Hamburg-Eppendorf.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Tanguay S, Bégin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59:261-5. [PMID: 11834399 DOI: 10.1016/s0090-4295(01)01497-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
OBJECTIVES To compare the performance of prostate-specific antigen (PSA), the free/total PSA (F/T PSA) ratio, and complexed PSA (cPSA) in prostate cancer detection. METHODS Five hundred thirty-five patients evaluated at the UROMED prostate cancer detection clinic had total PSA, free PSA, and cPSA measured before undergoing transrectal ultrasonography and sextant prostate biopsies. A direct comparison was performed between the different PSA assays to evaluate their ability to detect prostate cancer. RESULTS Of the 535 patients evaluated, 38.1% had prostate cancer detected. The mean age of the entire population was 63.6 years (range 35 to 86). Abnormal digital rectal examination findings were present in 33.4% of the patients. The mean and median values of PSA and cPSA were significantly higher and the F/T PSA ratio was lower in patients with prostate cancer. The F/T PSA ratio performed better than either cPSA or total PSA. A higher specificity was observed with the F/T PSA ratio than with cPSA using either the entire patient population or subsets of patients with PSA levels between 4.0 and 10 ng/mL or 4.0 to 6.0 ng/mL. CONCLUSIONS The use of the F/T PSA ratio offers improved prostate cancer detection compared with either cPSA or total PSA.
Collapse
Affiliation(s)
- S Tanguay
- Department of Surgery (Urology), McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | |
Collapse
|
32
|
Karakiewicz PI, Scardino PT, Kattan MW. The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP). Prostate Cancer Prostatic Dis 2000; 3:S21. [PMID: 12497131 DOI: 10.1038/sj.pcan.4500446] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P I Karakiewicz
- Department of Urology, Prostate Cancer Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | |
Collapse
|
33
|
Abstract
OBJECTIVES To assess the 30-day mortality rate and overall survival after radical retropubic prostatectomy (RRP). METHODS Identification of all RRPs performed in the Province of Quebec between January 5, 1988 and January 16, 1996 was accomplished through the Quebec Healthcare Plan Database. RESULTS Four thousand nine hundred ninety-seven RRPs were performed by 104 urologists. Overall, 451 deaths were recorded: 32 occurred during the first 30 days (0.6% 30-day mortality rate). A significant decrease in the 30-day mortality rate, from 2.45% to 0.5%, was recorded during the span of the study. The year of surgery, patient age, and hospital type were statistically significant short-term mortality variables (life table analysis). Patient age and year of surgery determined the cumulative survival probability (univariate and multivariate Cox analysis). Cumulative survival at 31 months of follow-up increased from 88.2% in 1988 to 98.1% in 1995. Men 75 years old and older were at a clear disadvantage with regard to survival probability compared with their younger counterparts. CONCLUSIONS In this population-based analysis of RRP outcomes, we demonstrated a significant improvement in short- and long-term outcomes, as evidenced by a decrease in the 30-day mortality rate and an improved cumulative survival, recorded over the span of the study. The recorded outcome trends may be explained by improved patient selection and optimal management. Although we are unable to determine cancer-specific outcomes, the results of this analysis should prove valuable to urologists and patients until there are results from randomized trials.
Collapse
Affiliation(s)
- P I Karakiewicz
- Department of Urology, McGill University, Montreal, Quebec, Canada
| | | | | | | | | |
Collapse
|
34
|
Karakiewicz PI, Aprikian AG. Prostate cancer: 5. Diagnostic tools for early detection. CMAJ 1998; 159:1139-46. [PMID: 9835884 PMCID: PMC1229783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
|
35
|
Abstract
OBJECTIVES To examine the use of radical retropubic prostatectomy (RRP) in a large population-based study. METHODS Identification of all RRPs performed in the province of Quebec between the years 1988 and 1993 was accomplished by relying on the Quebec Healthcare Plan Database. RESULTS Overall, 2861 RRPs have been performed during the study period. On average, 80% of surgeries have been performed by urologists using this surgery 12 times or less annually. Of all surgeries, 420 (15%) RRPs have been performed in individuals 71 years of age or older. CONCLUSIONS Each year, most RRPs (80%) in this population-based study were performed by urologists performing this procedure 12 times or less annually. A substantial proportion (15%) of RRPs have been performed in men 71 years of age or older, in whom the detriments of radical surgery may outweigh its benefits. These findings could potentially contribute to suboptimal outcomes when radical prostatectomy is compared with alternative treatment modalities.
Collapse
Affiliation(s)
- P I Karakiewicz
- Department of Urology, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
OBJECTIVES To assess the relationship between tumor volume, gland volume, number of sectors submitted to biopsy, and prostatic biopsy detection rate. METHODS Using a three-dimensional mathematical model of the prostate, we assessed detection rates achieved with 4-, 6-, 8-, 10-, and 12-sector biopsies for glands ranging from 20 to 100 cc and peripheral zone tumors ranging from 0.3 to 1.4 cc. RESULTS Quadrant and sextant biopsy approaches only yielded from 6.2% to 13.4% and 8.6% to 18.3%, respectively, of lesions in a 40-cc gland. Conversely, 10- and 12-sector approaches yielded, respectively, from 19.8% to 48.8% and 25.4% to 62% of lesions for the same gland size. When assessed according to the density of sampling, one biopsy core used for every 1 .5 to 3.5 cc of prostatic tissue detected 42.5% of 0.5-cc lesions. For the same lesion size, the density of sampling per biopsy core was then decreased to intervals extending from 3.6 to 7.5 cc, 7.6 to 12.5 cc, and 12.6 to 25 cc. These sampling density intervals yielded, respectively, 25.0%, 15.8%, and 9.8% detection rates. CONCLUSIONS On the basis of our results, a gland volume-based biopsy algorithm is likely to result in improved detection of clinically significant prostate cancer.
Collapse
Affiliation(s)
- P I Karakiewicz
- Department of Urology, McGill University, Montreal, Quebec, Canada
| | | | | |
Collapse
|
37
|
Karakiewicz PI, Herba MJ, Laplante M. A horseshoe kidney harboring large symptomatic renal angiomyolipoma with a false macro-aneurysm. Can J Urol 1997; 4:447-449. [PMID: 12735810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
We report a case of a large angiomyolipoma in a horseshoe kidney associated with a macro-aneurysm bleeding into the retroperitoneum. The patient was successfully treated by embolization of the macro-aneurysm, using thrombogenic cois and Ivalon particles. He remains free of symptoms at 18 months of follow-up. CT scan and renal ultrasound confirm no flow to the previous area of the macro-aneurysm and no change in size of the benign tumor.
Collapse
|
38
|
Karakiewicz PI, Aprikian AG, Bazinet M, Elhilali MM. Patient attitudes regarding treatment-related erectile dysfunction at time of early detection of prostate cancer. Urology 1997; 50:704-9. [PMID: 9372879 DOI: 10.1016/s0090-4295(97)00392-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVES To assess potency rate and patient attitudes regarding erectile dysfunction. METHODS A multiple choice, self-administered questionnaire distributed to 750 men undergoing testing for early detection of prostate cancer was used. RESULTS Overall, 33.9% of patients reported either partial or complete lack of erections and 31.1% were not sexually active or active less than once per month. Furthermore, 55.4% would be affected or very affected by lack of erections and 73.6% chose definitive treatment despite a 50% chance of erectile dysfunction. Finally, 47.4% found such treatment-induced erectile dysfunction to be an important or very important problem. When asked to ascribe a quantity of life or period of time that they would be willing to sacrifice to preserve sexual function following treatment, only 15.2% of patients were able to do so, but no consensus could be reached regarding its value. CONCLUSIONS Reported differences in quality-adjusted life expectancy when screening was compared to no screening and definitive therapy was compared to expectant management are marginal. Therefore, close attention to seemingly minor variables such as existing impotence rate, attitude regarding erectile dysfunction, and willingness to undergo therapy despite its inherent morbidity may substantially reduce or even reverse this reported disadvantage.
Collapse
Affiliation(s)
- P I Karakiewicz
- UROMED Prostate Cancer Detection Center, McGill University, Montreal, Canada
| | | | | | | |
Collapse
|
39
|
Bazinet M, Zheng W, Bégin LR, Aprikian AG, Karakiewicz PI, Elhilali MM. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 1997; 49:721-5. [PMID: 9145977 DOI: 10.1016/s0090-4295(97)00062-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Neoadjuvant androgen ablation (NAAA) causes significant cytoarchitectural changes in both benign and malignant prostatic epithelial cells that may contribute to underdetection of prostate cancer capsular involvement and positive surgical margins. METHODS The aim of this study is to determine the ability of cytokeratin immunohistochemistry to enhance the determination of pathologic stage of prostate cancer following NAAA. RESULTS Cytokeratin AE1/AE3 immunohistochemistry identified 6 (27.3%), 15 (68.2%), 5 (22.7%), and 5 (22.7%) cases of organ-confined disease, capsule penetration, positive surgical margin, and seminal vesicle involvement, respectively, as compared with 10 (45.5%), 10 (45.5%), 3 (13.6%), and 5 (22.7%) cases by hematoxylin-eosin (H&E) staining, respectively. Two cases without detectable tumor by H&E staining had demonstrable residual tumor by cytokeratin immunohistochemical staining. CONCLUSIONS Cytokeratin immunohistochemistry revealed more extensive intracapsular, capsular, and extracapsular tumor involvement and higher rate of positive surgical margin than did conventional H&E staining. Therefore, the beneficial pathologic effects of NAAA observed may, in part, be attributable to the artifact of observation.
Collapse
Affiliation(s)
- M Bazinet
- Department of Urology, McGill University, Montreal, Canada
| | | | | | | | | | | |
Collapse
|
40
|
Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachabé M, Péloquint F, Dessureault J, Goyal MS, Bégin LR, Elhilali MM. Outcome of sextant biopsy according to gland volume. Urology 1997; 49:55-9. [PMID: 9000186 DOI: 10.1016/s0090-4295(96)00360-3] [Citation(s) in RCA: 156] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVES To reassess positive rate of sextant biopsy according to gland size. METHODS We evaluated 1974 consecutive men with systematic sextant biopsy, among whom we examined biopsy yield according to gland-volume intervals of 10 cc. RESULTS Decreasing yield of sextant biopsy is strongly associated with increasing gland volume (P < 0.001). Highest biopsy rate (39.6%) was recorded among men with prostates smaller than 20 cc. The lowest biopsy rate (10.1%) was recorded among men with prostates between 80 and 89.9 cc. Among men with biopsy-proven cancer, age, serum prostate-specific antigen, and Gleason grade were comparable (P > 0.05) throughout the range of gland-volume intervals. CONCLUSIONS Our findings suggest that gland size represents an important determinant contributing to the yield of sextant biopsy in men at risk of harboring a nonpalpable, isoechoic cancer. Consequently, an individualized sector biopsy approach, based on prostate volume, may warrant consideration because it may ensure superior detection of clinically significant disease among all men at risk, regardless of prostate size.
Collapse
Affiliation(s)
- P I Karakiewicz
- UROMED Prostate Cancer Detection Center, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
OBJECTIVES To assess the potential difference in positive biopsy rates between four-sector and six-sector biopsy methods. METHODS This computer-assisted analysis is based on the records of 156 consecutive patients previously diagnosed with T1c cancer on systematic sextant biopsy of the peripheral zone. For each patient the computer randomly deleted one biopsy result from the left and right prostatic lobes. The deletion process was repeated 1000 times. Based on four randomly chosen biopsy cores, we determined the number of undetected cancers initially diagnosed with sextant biopsy. RESULTS Based on four-sector biopsy cores of the peripheral zone, between 6 and 30 (3.8% to 19.2% of cases) nonpalpable, isoechoic prostate cancers that were detected with sextant biopsy would have remained undiagnosed. CONCLUSIONS Our results suggest that the number of biopsy cores used in the early detection of nonpalpable, isoechoic prostate cancer may substantially affect the rate of positive findings.
Collapse
Affiliation(s)
- P I Karakiewicz
- UROMED Prostate Cancer Detection Center, Montréal, Québec, Canada
| | | | | | | |
Collapse
|
42
|
Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Péloquin F, Dessureault J, Goyal M, Bégin LR, Elhilali MM. Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. Urology 1996; 47:857-62. [PMID: 8677577 DOI: 10.1016/s0090-4295(96)00068-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVES To assess the accuracy and reproducibility of nonplanimetric transrectal ultrasound (TRUS) volume estimates because inaccurate volume estimates may potentially undermine the value of serum prostate-specific antigen density (PSAD) in early prostate cancer detection. METHODS We prospectively evaluated 535 consecutive male patients with two consecutive volume determinations performed by the same ultrasonographer at the time of the same visit. RESULTS Pearson correlation coefficients between two consecutive gland volume estimates ranged from 0.82 to 0.85 depending on the formula used; however, these correlation coefficients corresponded to an average 25% difference between the first and second gland volume estimates. CONCLUSIONS Although two consecutive nonplanimetric TRUS volume estimates show statistically good correlation, clinically up to a 25% volume difference should be expected between two such volume estimates. In consequence, nonplanimetric TRUS volume estimates should be interpreted with caution, especially when used for PSAD calculation, in the early detection of prostate cancer.
Collapse
Affiliation(s)
- M Bazinet
- Departments of Urology and Pathology, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Bazinet M, Karakiewicz PI, Aprikian AG, Trudel C, Aronson S, Nachabé M, Péloquin F, Dessureault J, Goyal M, Zheng W, Bégin LR, Elhilali MM. Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 1996; 155:605-6. [PMID: 8558670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
PURPOSE A prospective study was done to determine the value of performing 2 systematic transition zone biopsies in addition to systematic sextant peripheral zone biopsies for early detection of prostate cancer. MATERIALS AND METHODS From January 1 to August 31, 1994 we evaluated 847 consecutive patients referred to us for a suspicious lesion on digital rectal examination or an elevated serum prostate specific antigen level. All patients underwent 2 systematic transition zone biopsies in addition to systematic sextant biopsies of the peripheral zone. RESULTS Of the transition zone biopsies 68 (24.4%) contained malignancy, including only 8 (2.9%) with cancer found exclusively in the transition zone. The remaining 271 cases (97.1%) had 1 or more positive peripheral zone biopsies and would have been detected with or without additional systematic transition zone biopsies. The same analysis of 552 patients with a negative digital rectal examination yielded 6 (4.1%) exclusively transition zone tumors among 145 cancers detected in this group. CONCLUSIONS The low additional yield of transition zone biopsies (2.9 to 4.1%) does not warrant their systematic use for the early detection of prostate cancer.
Collapse
Affiliation(s)
- M Bazinet
- UROMED Prostate Cancer Detection Center, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|